Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 901–1,000 of 1,000
Moscetti, L. I., Fabbri, A., Natoli, C., Vici, P., Gamucci, T., Sperduti, I., Iezzi, L., Iattoni, E., Pizzuti, L., Roma, C. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17262 · Cited by 12
Locally Advanced Breast Cancer
da Costa, R. B., Hansen, N. M., & Gradishar, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00063-5 · Cited by 13
Chemical modulation of transcription factors
Wiedemann, B. M., Weisner, J., & Rauh, D. (2018) · MedChemComm · doi:10.1039/c8md00273h · Cited by 12
Ohe, R., Meng, H., Aung, N. Y., Yamada, A., Kabasawa, T., Utsunomiya, A., Tamazawa, N., Tamura, Y., Kitaoka, T., Hashimoto, T., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2577 · Cited by 12
“breast cancers expressing estrogen receptor (ER), progesterone receptor (PgR), or both.(1) A few studies identified possible differences in ERα, ERβ, and glucocorticoid receptor expression related to B‐cell”
BackgroundPalbociclib-Induced Pneumonitis: A Case Report and Review of the Literature
Sarkisian, S., Markosian, C., Ali, Z., & Rizvi, M. A. (2020) · Cureus · doi:10.7759/cureus.8929 · Cited by 12
Migliaccio, I., Leo, A., Galardi, F., Guarducci, C., Fusco, G. M., Benelli, M., Leo, A. D., Biganzoli, L., & Malorni, L. (2021) · Cancers · doi:10.3390/cancers13112640 · Cited by 12
Jeong, H., Jeong, J. H., Kim, J. E., Ahn, J., Jung, K. H., & Kim, S. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.205 · Cited by 12
Twelves, C. J., Bartsch, R., Ben-Baruch, N. E., Borštnar, S., Dirix, L. Y., Tesařová, P., Timcheva, C. V., Zhukova, L., & Pivot, X. B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.10.007 · Cited by 13
Law, E. H., Gavanji, R., Walsh, S., Haltner, A., McTavish, R. K., & Cameron, C. G. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0221 · Cited by 12
Canino, F., Piacentini, F., Omarini, C., Toss, A., Barbolini, M., Vici, P., Dominici, M., & Moscetti, L. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137079 · Cited by 13
Baş, O., Erul, E., Güven, D. C., & Aksoy, S. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07320-y · Cited by 16
Samjoo, I. A., Hall, A., Chen, C., Ngoc, N. B., Bartlett, M., Smith, M. L., Harbeck, N., Cappelleri, J. C., Karuturi, M. S., Makari, D., et al. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0111 · Cited by 13
Self-citationWander, S. A., Mayer, E. L., & Burstein, H. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9482 · Cited by 13
Oruç, Z., Ma, K., & Arslan, Ç. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504922 · Cited by 12
Cheng, Y., Li, N., Eapen, A., Parajuli, R., & Mehta, R. S. (2019) · Case Reports in Oncology · doi:10.1159/000501304 · Cited by 12
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer
Schneeweiß, A., Bauerfeind, I., Fehm, T. N., Janni, W., Thomssen, C., Witzel, I., Wöckel, A., Müller, V., & on behalf of the Commission Breast of the Working Group Gynecologic Oncology (AGO) (2020) · Breast Care · doi:10.1159/000511925 · Cited by 12
Kawashiri, T., Kobayashi, D., Uchida, M., Hiromoto, S., Inoue, M., Ikeda, H., Inoue, M., & Shimazoe, T. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31862 · Cited by 12
Zhong, B., Zhang, J., Wu, J., Sun, L., Li, S., Zeng, X., & Gan, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1002 · Cited by 13
Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
Arruabarrena-Aristorena, A., & Toska, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924808 · Cited by 14
“, palbociclib, ribociclib, abemaciclib) to anti-ER therapy have markedly prolonged survival compared to anti-ER therapy alone in ER+ metastatic breast cancers (3, 6).”
Results From a Health Insurer's Clinical Pathway Program in Breast Cancer
Gautam, S., Sylwestrzak, G., Barron, J. O., Chen, X., Eleff, M. K., Debono, D. J., Nguyen, A., & Fisch, M. J. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00157 · Cited by 13
Wang, R., Yang, Y., Ye, W.-W., Xiang, J., Chen, S., Zou, W., Wang, X., Chen, T., & Cao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.588080 · Cited by 16
A First Case of Male Breast Cancer Responding to Combined Aromatase Inhibitor/Palbociclib Therapy
Sorscher, S. M. (2016) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/3/5/1069 · Cited by 12
Stover, E. H., Feltmate, C. M., Berkowitz, R. S., Lindeman, N. I., Matulonis, U. A., & Konstantinopoulos, P. A. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00135 · Cited by 13
Telford, C., Jones, N., Livings, C., & Batson, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.02.007 · Cited by 11
Arndt, C., Tunger, A., Wehner, R., Rothe, R., Kourtellari, E., Luttosch, S., Hannemann, K., Koristka, S., Loureiro, L. R., Feldmann, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.970457 · Cited by 12
“, 2017), selective ER degraders, like fulvestrant (Turner et al., 2015; Sledge et al., 2017; Turner et al., 2018), or selective ER modulators as tamoxifen (Tripathy et al.”
BackgroundAn updated review on the role of small molecules in mediating protein degradation
Wu, Z., Li, Y., Dong, J., & Qin, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117370 · Cited by 11
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A. W., Layman, R. M., & Tripathy, D. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70055 · Cited by 23
Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle
Schiewer, M. J., & Knudsen, K. E. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.012 · Cited by 11
“…breast cancer in combination with estrogen deprivation or ER-targeted therapies (letrozole or fulvestrant, respectively) (Finn et al., 2015; Turner et al., 2015), based in part on clinical trial data demonstrating that the combination resulted in improved progression-free survival (PFS)…”
BackgroundBanys-Paluchowski, M. J., Krawczyk, N., & Paluchowski, P. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000511 · Cited by 11
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome
Plasterer, C., Tsaih, S., Peck, A. R., Chervoneva, I., O'Meara, C. C., Sun, Y., Lemke, A., Murphy, D., Smith, J. S., Ran, S., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05307-8 · Cited by 11
Seki, H., SAKURAI, T., MAEDA, Y., Oki, N., Aoyama, M., Yamaguchi, R., Tokuda, T., Kaburagi, T., OKUMURA, T., Karahashi, T., et al. (2019) · In Vivo · doi:10.21873/invivo.11701 · Cited by 13
Ribociclib in Breast Cancer Brain Metastases: A Case Report
Radke, I., von Wahlde, M., Schülke, C., & Tio, J. (2019) · Breast Care · doi:10.1159/000504405 · Cited by 11
Komorowski, A. S., MacKay, H. J., & Pezo, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3095 · Cited by 12
Park, S. Y., Suh, K. J., Lee, D., Ryu, H. S., Kim, M., Kim, S. H., Lee, K.-H., Kim, T., Kim, J. H., Park, I. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06566-8 · Cited by 12
Aydın, B., Beklen, H., Arğa, K. Y., Bayraklı, F., & Turanlı, B. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01923-2 · Cited by 12
Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
Gao, X., Wu, Y., Chick, J. M., Abbott, A., Jiang, B., Wang, J., Comte‐Walters, S., Johnson, R. H., Oberholtzer, N. P., Nishimura, M. I., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112314 · Cited by 12
Tokunaga, E., Miyoshi, Y., Dozono, K., Kawaguchi, T., & Toi, M. (2023) · The Oncologist · doi:10.1093/oncolo/oyad301 · Cited by 11
Borroni, R. G., Bartolini, M., Gaudio, M., Jacobs, F., Benvenuti, C., Gerosa, R., Tiberio, P., Manara, S. A. A. M., Solferino, A., Santoro, A., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae004 · Cited by 12
Cardiovascular complications of ribociclib in breast cancer patients
Fiste, O., Mavrothalassitis, E., Apostolidou, K., Trika, C. O., Liontos, M., Koutsoukos, K., Kaparelou, M., Dimitrakakis, C., Gavriatopoulou, M., Dimopoulos, M. A., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104296 · Cited by 11
Sedrak, M. S., Lee, M. K., Ji, J., Satele, D., Freedman, R. A., Poorvu, P. D., O’Connor, T. L., Williams, G. R., Hopkins, J. O., Muss, H. B., et al. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101813 · Cited by 12
The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer
Rossi, L., & Pagani, O. (2015) · Breast Care · doi:10.1159/000439462 · Cited by 11
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200715 · Cited by 11
Gelmon, K. A., Cristofanilli, M., Rugo, H. S., DeMichele, A. M., Joy, A. A., Castrellon, A. B., Sleckman, B. G., Mori, A., Theall, K. P., Lu, D. R., et al. (2019) · The Breast Journal · doi:10.1111/tbj.13516 · Cited by 11
Self-citationPreclinical discovery and development of abemaciclib used to treat breast cancer
Wright, M. D., & Abraham, J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1853097 · Cited by 12
ABC3 Consensus: Assessment by a German Group of Experts
Thomssen, C., Augustin, D., Ettl, J., Haidinger, R., Lück, H., Lüftner, D., Marmé, F., Marschner, N. W., Müller, L., Overkamp, F., et al. (2016) · Breast Care · doi:10.1159/000443515 · Cited by 11
Self-citationTrapé, A. P., Liu, S., Cortés, A., Ueno, N. T., & Gonzalez-Angulo, A. M. (2016) · Journal of Cancer · doi:10.7150/jca.14441 · Cited by 12
Generali, D., Montemurro, F., Bordonaro, R., Mafodda, A., Romito, S., Michelotti, A., Piovano, P., Ionta, M. T., Bighin, C., Sartori, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0461 · Cited by 11
Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups
Costa, R. L. B., & Gradishar, W. J. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2017.009936 · Cited by 12
Wang, J., Xu, B., Wang, W., Zhai, X., & Chen, X. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5047-9 · Cited by 11
Zeng, N., Han, J., Liu, Z., He, J., Tian, K., & Chen, N. (2023) · Cancers · doi:10.3390/cancers15133386 · Cited by 10
Rocque, G. B., Blum, J. L., Ji, Y., Pluard, T., Migas, J. J., Lakhanpal, S., Jepsen, E., Gauthier, E., Wang, Y., Montelongo, M. Z., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07524-2 · Cited by 10
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?
Das, G. M., Oturkar, C. C., & Menon, V. (2025) · Endocrinology · doi:10.1210/endocr/bqaf020 · Cited by 11
Trovarelli, G., Rizzo, A., Zinnarello, F. D., Cerchiaro, M., Angelini, A., Pala, E., & Ruggieri, P. (2025) · Current Oncology · doi:10.3390/curroncol32040226 · Cited by 10
“Additionally, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6), such as Palbociclib, Ribociclib, and Abemaciclib, prevent cancer cell proliferation by blocking the cell cycle [72].”
Jiang, X., Chen, Y., Gao, Y., Rong, R., Lai, Y., Zhu, Z., & Xu, Z. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115808 · Cited by 11
New agents for the management of resistant metastatic breast cancer
Anampa, J., & Sparano, J. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409206 · Cited by 12
Palbociclib-Induced Liver Failure
Atallah, R. P., Parker, N., Hamouche, K., Truong, Q. V., & Dingwall, M. (2020) · Kansas Journal of Medicine · doi:10.17161/kjm.v13i1.13628 · Cited by 10
Itzhaki, E., Hadad, E., Moskovits, N. B.-C., Stemmer, S. M., & Margel, S. (2021) · Pharmaceuticals · doi:10.3390/ph14070648 · Cited by 11
Lin, Y., Lin, J., Liu, Y.-E., Hsu, K., Hsieh, C., Chen, D.-R., & Wu, H. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101302 · Cited by 10
“In particular, PAL has demonstrated significant benefits in Phase II and III clinical trials (PALOMA-1, − 2 and − 3), doubling the progression-free survival (PFS) compared to letrozole or fulvestrant alone [28,29].”
BackgroundVijayakumar, J., Haddad, T. C., Gupta, K., Sauers, J., & Yee, D. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01317-4 · Cited by 10
Liu, Y., Dong, K., & Park, C. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411309 · Cited by 10
Sobrini-Morillo, P., Ravot, C., Herledan, C., Sánchez-Castellano, C., Cruz-Jentoft, A. J., & Falandry, C. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2024.01.003 · Cited by 10
Centrosomes and associated proteins in pathogenesis and treatment of breast cancer
Athwal, H., Kochiyanil, A., Bhat, V., Allan, A. L., & Parsyan, A. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1370565 · Cited by 11
Kaklamani, V. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0366 · Cited by 11
Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
Echavarría, I., Jerez, Y., Martín, M., & López‐Tarruella, S. (2017) · Breast Care · doi:10.1159/000481656 · Cited by 11
Warth, B., Palermo, A., Rattray, N. J. W., Lee, N. V., Zhu, Z., Hoang, L. T., Cai, Y. A., Mazurek, A., Dann, S. G., VanArsdale, T. L., et al. (2019) · Metabolites · doi:10.3390/metabo9010007 · Cited by 12
“The median PFS of 3.8 months (placebo/fulvestrant) was increased to 9.2 months for palbociclib/fulvestrant (Turner et al., 2015).”
BackgroundInfluentialCDK4/6 inhibitors in advanced breast cancer, what is beyond?
Mohammed, A. A., Rashied, H., & Elsayed, F. M. (2019) · Oncology Reviews · doi:10.4081/oncol.2019.416 · Cited by 11
Nicolini, A., Rossi, G., Ferrari, P., Morganti, R., & Carpi, A. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01881-3 · Cited by 10
A new treatment of alopecia induced by palbociclib: Topical cetirizine
Caro, G., Fortuna, M. C., Magri, F., Federico, A. D., Carlesimo, M., & Rossi, A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220930334 · Cited by 10
Ham, A., Cho, M., Won, H. S., Jo, J., & Lee, K. H. (2022) · Oncology Reports · doi:10.3892/or.2022.8341 · Cited by 10
Schreier, A., Munoz-Arcos, L. S., Soto, A. A., Sparano, J. A., & Anampa, J. D. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06574-8 · Cited by 11
Patient Case Lessons: Endocrine Management of Advanced Breast Cancer
Robert, N. J., & Denduluri, N. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.05.014 · Cited by 11
“treatment period in the palbociclib/fulvestrant group compared with fulvestrant monotherapy.(55)”
MethodResultHecht, K. A., & Selby, C. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018793656 · Cited by 11
Bayraktar, S., Batoo, S. A., Al‐Hattab, E., Basu, S., Okuno, S. H., & Glück, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0234 · Cited by 10
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
Parvathareddy, S. K., Siraj, A. K., Masoodi, T., Annaiyappanaidu, P., Al-Badawi, I. A., Al‐Dayel, F., & Al-Kuraya, K. S. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00827-8 · Cited by 10
Ngan, R. K. C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.11 · Cited by 11
Breast Cancer Diagnosis and Management
Goel, M. S., & Didwania, A. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_19 · Cited by 10
Iizumi, Y., Sowa, Y., Goi, W., Aono, Y., Watanabe, M., Kurumida, Y., Kameda, T., Akaji, K., Kitagawa, M., & Sakai, T. (2022) · Communications Biology · doi:10.1038/s42003-022-03522-6 · Cited by 10
Rajesh, A., Havas, A. P., Arnold, R., Lande, K., Lei, X., Li, K. Y., Gandhi, A., Franco, A. C., Woo, S., Lagnado, A. B., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01196-x · Cited by 10
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
Poggio, F. B., Lambertini, M., Blondeaux, E., Vaglica, M., Levaggi, A., Pronzato, P., & Mastro, L. D. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1215243 · Cited by 9
Masuda, N., Mukai, H., Inoue, K., Rai, Y., Ohno, S., Ohtani, S., Shimizu, C., Hashigaki, S., Muramatsu, Y., Umeyama, Y., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01162-4 · Cited by 9
Self-citationPalbociclib-induced severe hepatitis: A case study and literature review
Hyppolite, J. J., Rho, A., & Hilzenrat, N. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0015 · Cited by 10
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
Müller, V., Welslau, M., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1811-6148 · Cited by 9
Self-citationFundamental Considerations of Targeted Drug Therapies for Breast Cancer
Castillo‐Tobías, I., Berlanga, L., Poblano, J., Rodríguez‐Salazar, M. D. C., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3040043 · Cited by 10
Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not Metastasis
Bowley, T. Y., Merkley, S. D., Lagutina, I. V., Ortiz, M. C., Lee, M., Tawfik, B., & Marchetti, D. (2023) · Cancers · doi:10.3390/cancers15215263 · Cited by 9
“Conversely, palbociclib is a CDK4/6 inhibitor that has been widely used in many cancer therapies [38].”
BackgroundMethodKumar, A., Singh, A. K., Singh, H., Debbaraman, T., Pathak, P., Naumovich, V., Grishina, M., & Kumar, P. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142053 · Cited by 9
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Chen, W., Zhuang, X., Chen, Y., Yang, H., Shen, L., Feng, S., Min, W., Yuan, K., & Yang, P. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60846-6 · Cited by 17
Ohno, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.001 · Cited by 10
Same Data; Different Interpretations
Gyawali, B., & Prasad, V. K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2021 · Cited by 9
Value Assessment in Oncology Drugs: Funding of Drugs for Metastatic Breast Cancer in Canada
Lemieux, J., & Audet, S. (2018) · Current Oncology · doi:10.3747/co.25.3846 · Cited by 9
Davie, A. M., Carter, G. C., Rider, A., Bailey, A., Lewis, K., Price, G., Ostojic, H., Ringeisen, F. P., & Pivot, X. B. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100226 · Cited by 11
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
Lasala, R., Santoleri, F., Romagnoli, A., Abrate, P., Musicco, F., & Costantini, A. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002998 · Cited by 9
Yustos, M. A., Angulo, M. M., & Álvarez‐Mon, M. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.05.001 · Cited by 28
DeMichele, A. M., Robert, N. J., Chen, C., Kim, S., Zhang, Z., Lu, D. R., Aguilar, K. M., Wang, Y., Li, B. C., Schneeweiß, S., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00979-1 · Cited by 9
Albright, B. B., Shuey, S., Secord, A. A., Havrilesky, L. J., Berchuck, A., & Previs, R. A. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101297 · Cited by 11
“Several follow-up trials demonstrated improved survival and manageable side effect profile (Finn et al., 2015; Turner et al., 2015; Cristofanilli et al., 2016; Finn et al., 2016; Turner et al., 2018).”
BackgroundO’Connor, T. N., Schultz, E., Wang, J., O’Connor, T. L., Levine, E. G., Knudsen, E. S., & Witkiewicz, A. K. (2024) · Cancers · doi:10.3390/cancers16091749 · Cited by 11
“In HR+, HER2 − clinical presentations, endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy has become the standard of care [1–6].”
BackgroundBeith, J. M., Burslem, K., Bell, R. H., Woodward, N. E., McCarthy, N., BOER, R. D., Loi, S., & Redfern, A. D. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12491 · Cited by 9
Self-citationThe Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer
Rossi, L., & Pagani, O. (2017) · Journal of Women s Health · doi:10.1089/jwh.2017.6355 · Cited by 9
Mistry, R. A., Suri, G., Young, K. C., Hettle, R., May, J. R., Brixner, D. L., Oderda, G. M., BISKUPIAK, J. E., Tang, D. H., Bhattacharyya, D., et al. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1503484 · Cited by 10
Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
Kikuchi, M., Tanaka, Y., Yokota, M., Nishimiya, H., Katoh, H., Sengoku, N., & Kosaka, Y. (2019) · Biomedical Reports · doi:10.3892/br.2019.1248 · Cited by 9
Adverse events of targeted therapies reported by patients with cancer treated in primary care
Roger, S., Edeline, J., Campillo‐Gimenez, B., Ventroux, E., Bugat, M.-È. R., & Chapron, A. (2020) · European Journal of General Practice · doi:10.1080/13814788.2020.1846713 · Cited by 10
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.